Overview

Phase II/III Trial of CPT-11/5-FU/l-LV Versus CPT-11/TS-1 as Second Line Chemotherapy of Unresectable Colorectal Cancer

Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
This study is designed as Phase II/III. Phase II is aimed to evaluate safety and efficacy of IRIS, and feasibility of FOLFIRI. Phase III is aimed to verify inferiority of the progression free survival of IRIS in comparison with FOLFIRI.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Taiho Pharmaceutical Co., Ltd.
Collaborator:
Daiichi Sankyo Co., Ltd.
Treatments:
Camptothecin
Irinotecan